Jaguar Health Targets Mid-2027 NDA Filing for MVID with Potential End-2027 U.S. Approval
Jaguar Health (NASDAQ: JAGX) is aiming to file a New Drug Application (NDA) for its treatment of microvillus inclusion disease (MVID) by mid-2027, with the potential for FDA approval as early as late 2027. The company highlighted that this therapy could reduce parenteral nutrition support requirements in patients by up to 48%, a significant clinical benefit. During its Q2 2026 earnings call, CEO Lisa Conte emphasized transformation and strategic focus following the January 2026 out-license of Future Pak. She stated that Jaguar Health is now fully positioned as a rare disease gastrointestinal (GI) company with all resources dedicated to this therapeutic area.
Topics: pharmaceuticals rare diseases strategic transformation